Hi @johnrap, from the Ann it looks like we can expect the...

Hi @johnrap, from the Ann it looks like we can expect the following

• GLP Toxicity Study (Q1)
• HREC submission and approval (Q1) - in another of my stocks the HREC committee for the hospital of the trial only meets once per month, I'm not sure how it will work for us given Linear are conducting the trails which will hopefully make this process quicker
• Patient recruitment hopefully set to start H1 and put us holders who have been waiting for the transition from pre-clinical to clinical company out of our misery

Whilst the announcement disclosed some new results that further bolster the already very impressive drug profile of EmtinB (e.g. 98% of the drug makes it to the site of treatment), I am of the opinion that only clinical trials beginning can send us on an upward trajectory as we shake the title of preclinical company and assume clinical company, so once trails begin we count down the days until the results when NSB can wave in Big Pharmas face that this drug is safe in humans (which is what ex-chair Brian Leedman said was their biggest concern)

Goodluck holders hopefully not much longer yet to wait and that the Glaucoma trial can begin H1 2022 as well.